Bioject announces the appointment of a distributor for China

May 12, 2014

TIGARD, Ore., May 12, 2014 /PRNewswire/ — Bioject Medical Technologies Inc. (OTC Pink: BJCT), a leading developer of needle-free injection systems continues to expand global access to the company’s technology. Bioject has signed an agreement with Caligor RX, Inc. to use its China distribution partners to sell its commercial devices in the region.

“We are looking forward to working with Bioject to bring this important technology to the People’s Republic of China,” commented Joseph Safdie, Caligor RX Vice President and Corporate Counsel, “We anticipate a successful collaboration that will provide a significant benefit to public health in China.”

“Caligor RX has an extensive network of business resources in China that will provide an exceptional base for marketing and sales of our products,” stated Mark Logomasini, Bioject’s President and CEO. “This agreement represents a significant step forward in the company’s goal of establishing itself as the standard in needle-free technology around the world, particularly in areas where there is an acute appreciation of the public health consequences of needle-stick injuries.”

Bioject Medical Technologies Inc., based in Tigard, Oregon, USA, is a developer and manufacturer of needle-free injection therapy systems (NFITS). NFITS works by forcing medication at high speed through a tiny orifice held against the skin. This creates a fine stream of high-pressure fluid penetrating the skin and depositing medication in the tissue beneath. Bioject is focused on developing mutually beneficial agreements with leading pharmaceutical, biotechnology, and veterinary companies, as well as research, global health and government organizations.

Caligor Rx is an international pharmaceutical supply company engaged in efficient, cost-effective sourcing and supply of comparator drugs for clinical trials worldwide. Caligor Rx is licensed to ship all drugs, including Schedules II-V, anywhere in the world. Headquartered in Secaucus with facilities in Europe, the company’s operations include state-of-the art warehousing and distribution, complete with monitored cold chain and ambient storage capabilities. Through our relationships with leading manufacturers and suppliers, we specialize in helping our customers put the right comparator sourcing strategy in place for their needs.

Readers and potential investors are cautioned that an investment in the Bioject’s securities involve an EXTREMELY high degree of risk. Such risks include, without limitation, the risk that the distribution agreement will not be successful due to the time required in obtaining government clearances and the risk that the Company may be unable to comply with the extensive government regulations applicable to the international business.

Bioject (OTC Pink: BJCT) trades on the OTC Pink tier of the OTC market. Investors can find Real-Time quotes and market information for the Company on www.otcmarkets.com.

For more information about Bioject and CaligorRX visit www.bioject.com and www.CaligorRx.com respectively.

SOURCE Bioject Medical Technologies Inc.

Source: PR Newswire

comments powered by Disqus